Loading...
OTCM
SHBTF
, Last price  
USD
Name

Shanghai Haohai Biological Technology Co Ltd

Chart & performance

D1W1MN
OTCM:SHBTF chart
P/E
—
P/S
—
EPS
1.07
Vol. 1Y
—
Shs. 5Y
5.57%
Rev. 5Y
13.06%
Div Yld LY
—
Div Yld TTM
—
Revenues
2.45b
-8.71%
303,065,000401,088,000515,940,000663,917,000851,157,0001,344,856,0001,545,824,0001,595,498,0001,324,427,0001,750,116,0002,103,438,0002,634,910,0002,679,667,0002,446,306,000
Net income
245m
-41.85%
113,942,000141,521,000183,582,000273,474,000305,052,000372,415,000414,540,000370,779,000230,072,000352,234,000180,470,000416,121,000420,447,000244,509,783
CFO
629m
-3.09%
118,420,000146,906,000141,993,000268,511,000254,485,000343,059,000391,284,000348,911,000262,073,000342,286,000231,296,000634,450,000648,572,000628,501,638

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

Shanghai Haohai Biological Technology Co., Ltd. is a global enterprise dedicated to the research, development, manufacturing, and commercialization of biomedical materials. Its operations span Mainland China, the United States, the United Kingdom, and various other international regions. A comprehensive product portfolio addresses several key medical disciplines. Within ophthalmology, offerings include intraocular lenses, ophthalmic viscoelastic devices, orthokeratology and phakic refractive lenses, eye drops, injectors, and surgical scalpels. Orthopedics products encompass sodium hyaluronate injections and medical chitosan. For wound repair, it manufactures recombinant human epidermal growth factor, effective in treating burn wounds, residual wounds, donor site post-traumatic wounds, and both fresh and chronic ulcerations. Additionally, the company develops anti-adhesion materials, including medical sodium hyaluronate gel and medical chitosan, as well as hemostatic solutions such as collagen sponges and porcine fibrin sealants. Beyond its therapeutic offerings, Shanghai Haohai maintains a significant presence in the medical aesthetics market. This segment features a range of hyaluronic acid (HA) dermal fillers: Matrifill, positioned as a first-generation mono-phase injectable HA gel; Janlane, a second-generation filler engineered for dynamic application; and Hyalumatrix, a third-generation product providing precise aesthetic embellishment. Its aesthetic portfolio is further complemented by radio frequency devices and laser equipment. Furthermore, the company actively engages in the research and development of biological engineering and pharmaceutical products, extending services such as technology transfer and consultation. It also conducts investment and trading operations. Established in 2007, the entity initially traded as Haohai Limited before officially adopting the name Shanghai Haohai Biological Technology Co., Ltd. in 2010. Its corporate headquarters are based in Shanghai, China.

Key people

Wenbin Wang
Deputy General Manager · since 2019
Jundong Zhang
Deputy General Manager · since 2019
Yiyi Chen
Executive Director · since 2014
Yongtai Hou
Chairman of the Board, Executive Director · since 2014
Minjie Tang
Finance Director, Executive Director · since 2017
Jianying Wu
General Manager, Executive Director · since 2014
Min Tian
Secretary of the Board, Joint Company Secretary · since 2020
Changzheng Wei
Staff Representative Director · since 2025
Non-Executive Director · since 2019
Jie You
Non-Executive Director · since 2019
Zhihong Jiang
Independent Non-Executive Director · since 2020
Yingqi Li
Independent Non-Executive Director
Hongbo Shen
Independent Non-Executive Director · since 2023
Zhi Su
Independent Non-Executive Director · since 2020
Yushe Yang
Independent Non-Executive Director · since 2020
Lei Zhao
Independent Non-Executive Director · since 2020
IPO date
Apr 30, 2015
Employees
2,123
Domiciled in
CN
Incorporated in
CN
Legal address
No. 5, Dongjing Road, Songjiang Industrial Zone
Shanghai, SH
CN
Headquarters
23/F, WenGuang Plaza,No. 1386, Hongqiao Road, Changning District
Shanghai, SH 200052
CN

Valuation

Title
CNY in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2025‑122024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT